Revance Therapeutics, Inc. (RVNC)
Feb 6, 2025 = RVNC was delisted (reason: acquired by Crown Laboratories)
3.650
0.00 (0.00%)
Inactive · Last trade price on Feb 6, 2025
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Revance Therapeutics stock had an average target of 7.78, with a low estimate of 3.00 and a high estimate of 20.
Price Target: $7.78 (+113.15%)
Analyst Consensus: Hold
* Price targets were last updated on Dec 23, 2024.
Analyst Ratings
The average analyst rating for Revance Therapeutics stock from 9 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 1 | 1 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 7 | 7 | 6 | 7 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 11 | 10 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 17, 2025 |
| Barclays | Barclays | Hold Maintains $7 → $3 | Hold | Maintains | $7 → $3 | -17.81% | Dec 23, 2024 |
| Mizuho | Mizuho | Hold Maintains $6.66 → $3.1 | Hold | Maintains | $6.66 → $3.1 | -15.07% | Dec 10, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $6.6 | Hold | Reiterates | $6.6 | +80.82% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
260.43M
from 234.04M
Increased by 11.28%
Revenue Next Year
331.29M
from 260.43M
Increased by 27.21%
EPS This Year
-1.63
from -3.83
EPS Next Year
-1.11
from -1.63
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 294.4M | 356.4M | ||||
| Avg | 260.4M | 331.3M | ||||
| Low | 236.3M | 279.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 25.8% | 36.9% | ||||
| Avg | 11.3% | 27.2% | ||||
| Low | 1.0% | 7.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.65 | -0.70 | ||||
| Avg | -1.63 | -1.11 | ||||
| Low | -1.61 | -1.45 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.